T
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
Investor insights
Funding rounds participated in
$250M sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2011
Funding rounds raised
Total raised
$250M
from 2 investors over 1 rounds
T
TG Therapeutics, Inc. raised $250M on September 6, 2024
Investors: HealthCare Royalty Partners and Blue Owl